With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Former India coach Ravi Shastri has urged Virat Kohli to quickly regain his form after the star batter struggled in the ongoing ODI series against Australia. Kohli, returning to international cricket ...

Tech stocks and top consumer names are increasingly at risk of steep declines in a slowing economy. Click here to see 5 ...

This article was reviewed by Knox Beasley, MD. Rogaine vs Minoxidil: What’s Best for Hair Growth? Growing up, you may have longed for the new, cool ...

Industry shift prioritizes AI experience over hardware, revolutionizing consumer tech engagement GenAI enables real-time capabilities like image editing and personalized content creation on premium ...

Scott Allan got an early insight into Kieran Tierney ’s drive as a member of the same car pool making the daily trip to Lennoxtown. That was a decade ago when he was in his first season with Celtic ...

Investing.com - FormFactor (NASDAQ: FORM) reported third quarter EPS of $0.33, $0.08 better than the analyst estimate of $0.25.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...

IMAGE: Shreyas Iyer laboured against the short ball before gloving a catch to the keeper for 11. Photograph: Amit Dave/Reuters Shreyas Iyer’s battle against Josh Hazlewood continued on a rain-hit ...